No Image

Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy SHANGHAI, China, and REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Shanghai Jun...
read more
No Image

General Fusion achieves critical technology milestone for practical fusion power

Successful performance of plasma compression prototype confirms path to commercialization General Fusion’s plasma compression prototype VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) — General Fusion announced today it has successfully achieve...
read more
No Image

2022 A4BET® Worldwide Domain & Trademark Sale

BEIJING and LONDON and PARIS and SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) — After overwhelming demand, creative offers and global inquires from it’s recent September 2021 billion dollar auction, A4BET® is announcing a time sensitive bidding process t...
read more
No Image

British Fishing Tackle & Bait Scales Order Fulfillment Processing 250% with Descartes Ecommerce WMS

CHIPPENHAM, United Kingdom, Jan. 10, 2022 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that UK-based sports and hobbies retailer Fishing Tackle & ...
read more
No Image

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing...
read more
No Image

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral infection on the point-of-need platform MeMed Key® HAIFA, I...
read more
No Image

Nyxoah Provides General Corporate Update

Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq...
read more
No Image

Formosa Plastics to give year-end bonuses of 7 months’ salary

Formosa Plastics Group (FPG) said on Monday that it would dole out year-end bonuses equivalent to seven months' basic salary to employees of the conglomerate's four major entities.In a statement, FPG said its general management department had made the ...
read more
No Image

CORONAVIRUS/Domestic COVID-19 cases linked to airport climb to 30 (update)

Taiwan on Monday confirmed six new domestic COVID-19 cases, all linked to Taoyuan International Airport, and 26 new imported cases, according to the Central Epidemic Command Center (CECC).The six new cases, which include one confirmed by the CECC late ...
read more